Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Editas Medicine (EDIT)

Editas Medicine (EDIT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference GlobeNewswire - Thu May 28, 3:01PM CDT

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced...

EDIT : 3.04 (-3.80%)
Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering GlobeNewswire - Tue May 26, 8:05AM CDT

CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the...

EDIT : 3.04 (-3.80%)
Editas Medicine Announces Proposed Public Offering GlobeNewswire - Tue May 26, 5:15AM CDT

CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced that...

EDIT : 3.04 (-3.80%)
Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress GlobeNewswire - Tue May 26, 5:01AM CDT

Single dose of EDIT-401 achieved ~90% or greater mean reductions in LDL-C, Lp(a), and ApoB in non-human primates Data reinforce differentiated LDLR upregulation approach with rapid, dose-dependent...

EDIT : 3.04 (-3.80%)
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting GlobeNewswire - Thu May 14, 5:01AM CDT

CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical...

EDIT : 3.04 (-3.80%)
Editas: Q1 Earnings Snapshot AP - Tue May 5, 6:16AM CDT

Editas: Q1 Earnings Snapshot

EDIT : 3.04 (-3.80%)
Editas Medicine Announces First Quarter 2026 Results and Business Updates GlobeNewswire - Tue May 5, 6:00AM CDT

EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, on track to achieve early human proof-of-concept data by year-end 2026  Company to present new EDIT-401 preclinical...

EDIT : 3.04 (-3.80%)
Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences GlobeNewswire - Mon Apr 27, 3:31PM CDT

CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today...

EDIT : 3.04 (-3.80%)
Medical research and development by Gorodenkoff via Shutterstock
CRISPR Therapeutics: The Fundamental Standard-Bearer in a Fractured Genomic Sector Trade The Pool - Tue Mar 31, 7:00AM CDT

With $116 million in FY2025 product revenue and a $2.0 billion cash reserves, CRSP has separated itself from pre-commercial peers — but the path forward demands clear eyes on both opportunity and risk....

CRSP : 51.37 (+1.80%)
EDIT : 3.04 (-3.80%)
NTLA : 13.04 (-1.95%)
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference GlobeNewswire - Fri Mar 27, 6:00AM CDT

CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today...

EDIT : 3.04 (-3.80%)

Barchart Exclusives

This Dividend Stock Trading Near Multi-Year Lows Is a Risky Buy With Significant Upside Potential Barchart - Wed Jul 15, 6:30PM CDT
FMC stock is trading near the lowest level in over two decades as the company continues to battle several challenges. It, however, can be a speculative buy for aggressive investors given the low valuations. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.